Abstract
Basal cell carcinoma (BCC) is the most frequent human skin cancer, but metastasizing BCC (MBCC) is extremely rare, developing in approximately 0.0028% to 0.55% of BCC patients. Herein, we report two cases of pulmonary MBCC. The first one developed in a 72-year-old male who underwent surgical resection due to multiple recurrences and adjuvant radiotherapy. Immunohistochemistry showed that neoplastic cells expressed Ber-EP4, CK5/6, p63, EMA (focally), BCL-2, and CD10, but were negative for CK7, CK20, S100, estrogen and progesterone receptors, and TTF-1. The second case is a 64-year-old female treated with vismodegib. Clinicopathological features and differential diagnoses are described.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference33 articles.
1. Update in the Management of Basal Cell Carcinoma;Herms;Acta Derm. Venereol.,2020
2. Systemic Therapy for Disseminated Basal Cell Carcinoma: An Uncommon Manifestation of a Common Cancer;Ganti;Cancer Treat. Rev.,2011
3. The Incidence and Clinical Analysis of Non-Melanoma Skin Cancer;Lange;Sci. Rep.,2021
4. Trends in Basal Cell Carcinoma Incidence Rates: A 16-Year Retrospective Study of a Population in Central Poland;Narbutt;Adv. Dermatol. Allergol.,2018
5. Ramchatesingh, B., Gantchev, J., Martínez Villarreal, A., Gill, R.P.K., Lambert, M., Sivachandran, S., Lefrançois, P., and Litvinov, I.V. (2022). The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas. Cancers, 14.